Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

MEC.4 (Alliance A091201) - Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma - was closed to accrual on May 6, 2016. Closure was recommended by the Alliance DSMC following demonstration of futility after a recent interim analysis.

Thanks to all participating member centres, staff and patients for participating in this study.